In response to COVID-19, ACG takes measures to ensure workforce & public health

As a key pharma supply player, ACG is committed to working with its partners to ‘make the world healthier’. This means that of primary concern is the health of all people – around the world, and also in its own workplace.

So, in light of an escalation in the severity of the coronavirus pandemic – and effective immediately – ACG has mandated that wherever business functions allow, employees around the world should now work from home.

ACG is encouraging its staff to make use of all available IT solutions, and has committed to covering the associated expenses of working remotely. Furthermore, a company-wide ban on travel has been imposed, and participation at events and exhibitions suspended.

ACG has also taken proactive preventative measures to ensure the safety of factory bound workers, including daily screening with thermal scanners, providing easy access to sanitisers, and regular cleaning of all workspaces and commute buses. A crisis plan has also been developed in case an emergency situation arises.

In this time of medical crisis, and in support of its pharma partners, ACG has reaffirmed its commitment to providing uninterrupted supply of its products and services, and factories in all locations around the world are working at full capacity. The company has also taken proactive measures to ensure supply of its own raw materials for many months.

On the measures taken to fight COVID-19, Sunil Jha, Group CHRO of ACG said: “We are doing everything we possibly can to safeguard  the health of our associates and communities, while also ensuring our ability to honour commitments made to pharmaceutical customers in terms of meeting their increased requirements.

“These are unprecedented times calling for unprecedented measures, and we promise to stand strong alongside all healthcare providers fighting on the front lines of this pandemic.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Related news

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...